Skip to main content

Readmission After Lobectomy for Lung Cancer: Not All Complications Contribute Equally.

Publication ,  Journal Article
Brown, LM; Thibault, DP; Kosinski, AS; Cooke, DT; Onaitis, MW; Gaissert, HA; Romano, PS
Published in: Ann Surg
July 1, 2021

OBJECTIVE: The aim of this study was to identify independent predictors of hospital readmission for patients undergoing lobectomy for lung cancer. SUMMARY BACKGROUND DATA: Hospital readmission after lobectomy is associated with increased mortality. Greater than 80% of the variability associated with readmission after surgery is at the patient level. This underscores the importance of using a data source that includes detailed clinical information. METHODS: Using the Society of Thoracic Surgeons (STS) General Thoracic Surgery Database (GTSD), we conducted a retrospective cohort study of patients undergoing elective lobectomy for lung cancer. Three separate multivariable logistic regression models were generated: the first included preoperative variables, the second added intraoperative variables, and the third added postoperative variables. The c statistic was calculated for each model. RESULTS: There were 39,734 patients from 277 centers. The 30-day readmission rate was 8.2% (n = 3237). In the final model, postoperative complications had the greatest effect on readmission. Pulmonary embolus {odds ratio [OR] 12.34 [95% confidence interval (CI),7.94-19.18]} and empyema, [OR 11.66 (95% CI, 7.31-18.63)] were associated with the greatest odds of readmission, followed by pleural effusion [OR 7.52 (95% CI, 6.01-9.41)], pneumothorax [OR 5.08 (95% CI, 4.16-6.20)], central neurologic event [OR 3.67 (95% CI, 2.23-6.04)], pneumonia [OR 3.13 (95% CI, 2.43-4.05)], and myocardial infarction [OR 3.16 (95% CI, 1.71-5.82)]. The c statistic for the final model was 0.736. CONCLUSIONS: Complications are the main driver of readmission after lobectomy for lung cancer. The highest risk was related to postoperative events requiring a procedure or medical therapy necessitating inpatient care.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ann Surg

DOI

EISSN

1528-1140

Publication Date

July 1, 2021

Volume

274

Issue

1

Start / End Page

e70 / e79

Location

United States

Related Subject Headings

  • Surgery
  • Risk Factors
  • Retrospective Studies
  • Postoperative Complications
  • Pneumonectomy
  • Perioperative Period
  • Patient Readmission
  • Middle Aged
  • Male
  • Lung Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Brown, L. M., Thibault, D. P., Kosinski, A. S., Cooke, D. T., Onaitis, M. W., Gaissert, H. A., & Romano, P. S. (2021). Readmission After Lobectomy for Lung Cancer: Not All Complications Contribute Equally. Ann Surg, 274(1), e70–e79. https://doi.org/10.1097/SLA.0000000000003561
Brown, Lisa M., Dylan P. Thibault, Andrzej S. Kosinski, David T. Cooke, Mark W. Onaitis, Henning A. Gaissert, and Patrick S. Romano. “Readmission After Lobectomy for Lung Cancer: Not All Complications Contribute Equally.Ann Surg 274, no. 1 (July 1, 2021): e70–79. https://doi.org/10.1097/SLA.0000000000003561.
Brown LM, Thibault DP, Kosinski AS, Cooke DT, Onaitis MW, Gaissert HA, et al. Readmission After Lobectomy for Lung Cancer: Not All Complications Contribute Equally. Ann Surg. 2021 Jul 1;274(1):e70–9.
Brown, Lisa M., et al. “Readmission After Lobectomy for Lung Cancer: Not All Complications Contribute Equally.Ann Surg, vol. 274, no. 1, July 2021, pp. e70–79. Pubmed, doi:10.1097/SLA.0000000000003561.
Brown LM, Thibault DP, Kosinski AS, Cooke DT, Onaitis MW, Gaissert HA, Romano PS. Readmission After Lobectomy for Lung Cancer: Not All Complications Contribute Equally. Ann Surg. 2021 Jul 1;274(1):e70–e79.

Published In

Ann Surg

DOI

EISSN

1528-1140

Publication Date

July 1, 2021

Volume

274

Issue

1

Start / End Page

e70 / e79

Location

United States

Related Subject Headings

  • Surgery
  • Risk Factors
  • Retrospective Studies
  • Postoperative Complications
  • Pneumonectomy
  • Perioperative Period
  • Patient Readmission
  • Middle Aged
  • Male
  • Lung Neoplasms